Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Inmed Pharmaceuticals Inc (INM)

Inmed Pharmaceuticals Inc (INM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
InMed Pharmaceuticals’ (NASDAQ: INM) BayMedica Poised as Rare Cannabinoids Drive Market Growth

InMed Pharmaceuticals’ (NASDAQ: INM) subsidiary BayMedica is positioned amid a growing interest in edibles infused with non-intoxicating minor cannabinoids. These lesser-known cannabinoids offer unique...

INM : 0.2749 (-1.22%)
InMed Pharmaceuticals’ (NASDAQ: INM) INM-901: A Promising Candidate for Alzheimer’s

InMed Pharmaceuticals (NASDAQ: INM), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors, announced that...

INM : 0.2749 (-1.22%)
InMed Pharmaceuticals (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901

InMed Pharmaceuticals (NASDAQ: INM), a biopharmaceutical company focused on developing proprietary small molecule drug candidates for diseases with high unmet needs, has announced promising outcomes from...

INM : 0.2749 (-1.22%)
InMed Pharmaceuticals (NASDAQ: INM) Announces Three U.S. Patent Issuances

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary small molecule drug candidates, today announced its receipt of...

INM : 0.2749 (-1.22%)
InMed Pharmaceuticals (NASDAQ: INM) Announces Exciting INM-901 Data

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced that recent data from preclinical...

INM : 0.2749 (-1.22%)
InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

InMed's intellectual property portfolio totals 13 patent families covering new chemical entities, formulations, manufacturing methods and methods of useVancouver, British Columbia--(Newsfile Corp. - August...

INM : 0.2749 (-1.22%)
InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

High bioavailability of INM-901 oral formulation provides similar drug concentration levels in the brain as intraperitoneal (IP) injectionVancouver, British Columbia--(Newsfile Corp. - August 20, 2024)...

INM : 0.2749 (-1.22%)
InMed Pharmaceuticals’ (NASDAQ: INM) INM-089 Showing Great Promise in Treating AMD

InMed Pharmaceuticals (NASDAQ: INM), a clinical stage company developing a pipeline of pharmaceutical drug candidates to treat several diseases with a high unmet medical need, is at the forefront of developing...

AMD : 153.93 (+3.80%)
INM : 0.2749 (-1.22%)
InMed Pharmaceuticals (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”

With the increasing acceptance of cannabis use in society, the popularity of edibles—products containing cannabinoids that can be consumed as food or drink—has surged. While many consumers are familiar...

INM : 0.2749 (-1.22%)
InMed Pharmaceuticals (NASDAQ: INM) Reports Long-Term Study Results on Treatment for AD

InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, is reporting on...

INM : 0.2749 (-1.22%)

Barchart Exclusives

Should You Follow Insider Buying on This Energy Dividend Stock?
The article examines whether investors should follow insider buying on a promising energy dividend stock. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar